APA

Tiberghien P., Racadot E., Fest T., Lioure B., Pariset J., Delain M., Voillat L., Flesch M., Amsallem D. & Plouvier E. (19910927). IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?. : Bone marrow transplantation.

Chicago

Tiberghien P, Racadot E, Fest T, Lioure B, Pariset J, Delain M, Voillat L, Flesch M, Amsallem D and Plouvier E. 19910927. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?. : Bone marrow transplantation.

Harvard

Tiberghien P., Racadot E., Fest T., Lioure B., Pariset J., Delain M., Voillat L., Flesch M., Amsallem D. and Plouvier E. (19910927). IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?. : Bone marrow transplantation.

MLA

Tiberghien P, Racadot E, Fest T, Lioure B, Pariset J, Delain M, Voillat L, Flesch M, Amsallem D and Plouvier E. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?. : Bone marrow transplantation. 19910927.